ReviewJournal of the American Heart Association2023
Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: For Whom and How.
Review in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Assessment of Myocardial Viability in Ischemic Cardiomyopathy With Reduced Left Ventricular Function Undergoing Coronary Artery Bypass Grafting.Clinical cardiology · 2024Pooled it
- Comparative evaluation of PET quantitative methods for myocardial viability assessment in CAD patients and its prognostic value.The international journal of cardiovascular imaging · 2026Article
- Invasive and medical management approaches to non-acute myocardial ischaemic syndromes.Nature reviews. Cardiology · 2026Review
- Topical vascular organoid therapy promotes microvascular regeneration and functional recovery in porcine ischemic cardiomyopathy.Stem cell reports · 2026Article
- Left Ventricular Ejection Fraction Trajectory and Long-Term Outcomes Following Percutaneous Coronary Intervention for Myocardial Infarction.JACC. Advances · 2026Article
- State-of-the-art management of ischemic cardiomyopathy: integrating diagnostic pathways, revascularization strategies, and guideline-directed therapy.Heart failure reviews · 2026Review
- Macrophage Cluster of Differentiation 163 promotes post-infarction cardiac repair and preserves left ventricular function via osteopontin.Clinical and translational medicine · 2026Article
- Overall coronary disease burden modifies the prognostic benefit of CTO-PCI: a SYNTAX score-stratified meta-analysis.European heart journal open · 2026Article
- Synthetic Contrast-Free LGE via Diffusion-Based Framework in Acute MI for Image Quality and Quantitative Scar Analysis.Circulation. Cardiovascular imaging · 2026Article
- Insulin or Dapagliflozin Potentially Improves Microcirculatory Dysfunction or INOCA Related to Culprit Vessels in Diabetic Patients With STEMI After DCB Therapy During Long-Term Follow-Up.Journal of diabetes · 2026Observational
- More Is Better for Blood-Seeking Ischemic Myocardium.Korean circulation journal · 2026Article
- Single Versus Multiple Inflow Source for Coronary Artery Bypass Surgery in Ischemic Cardiomyopathy.Korean circulation journal · 2026Article
- Can dobutamine stress echocardiography predict improvement of left ventricular dyssynchrony after coronary artery bypass grafting?Caspian journal of internal medicine · 2026Article
- Newly-engineered angiopoietin-1 as a cell-priming agent for CVD.Cellular and molecular life sciences : CMLS · 2025Article
- Circulatory Support for High-Risk Coronary Artery Bypass Grafting and Coronary Interventions: Where is the Evidence?The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Review
- Guideline for Chronic Coronary Syndrome - 2025.Arquivos brasileiros de cardiologia · 2025Article
- The Contemporary Role of Cardiovascular Magnetic Resonance in Ischemic Cardiomyopathy.Journal of clinical medicine · 2025Review
- Rapid manufacturing of angiogenic cellular collagen patches for ischemic cardiomyopathy.Stem cells translational medicine · 2025Article
- Identification of clinical phenotypes and heterogeneous treatment effects of surgical revascularization in ischaemic cardiomyopathy: a machine learning consensus clustering analysis.European heart journal. Digital health · 2025Article
- The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Myocardial revascularization has been advocated to improve myocardial function and prognosis in ischemic cardiomyopathy (ICM). We discuss the evidence for revascularization in patients with ICM and the role of ischemia and viability detection in guiding treatment. Methods and Results We searched for randomized controlled trials evaluating the prognostic impact of revascularization in ICM and the value of viability imaging for patient management. Out of 1397 publications, 4 randomized controlled trials were included, enrolling 2480 patients. Three trials (HEART [Heart Failure Revascularisation Trial], STICH [Surgical Treatment for Ischemic Heart Failure], and REVIVED [REVascularization for Ischemic VEntricular Dysfunction]-BCIS2) randomized patients to revascularization or optimal medical therapy. HEART was stopped prematurely without showing any significant difference between treatment strategies. STICH showed a 16% lower mortality with bypass surgery compared with optimal medical therapy at a median follow-up of 9.8 years. However, neither the presence/extent of left ventricle viability nor ischemia interacted with treatment outcomes. REVIVED-BCIS2 showed no difference in the primary end point between percutaneous revascularization or optimal medical therapy. PARR-2 (Positron Emission Tomography and Recovery Following Revascularization) randomized patients to imaging-guided revascularization versus standard care, with neutral results overall. Information regarding the consistency of patient management with viability testing results was available in ≈65% of patients (n=1623). No difference in survival was revealed according to adherence or no adherence to viability imaging. Conclusions In ICM, the largest randomized controlled trial, STICH, suggests that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.